secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2021-12-14T23:59:59+00:00
Accession:  0001193125-21-356869
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia names Mark Schneyer permanent CFO; previously interim CFO since Sept 2021
--------------------------------------------------------------------------------

- Mark Schneyer appointed EVP, CFO effective Dec 9, 2021; had served as interim CFO since Sept 2021.
- Schneyer previously SVP, Business Development and CBO; joined Acadia from Pfizer in May 2020.
- He led the Dec 2020 acquisition of CerSci Therapeutics, adding a Phase 2-ready pain program.
- Schneyer retains responsibility for business development and investor relations; reports to CEO Steve Davis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312521356869/0001193125-21-356869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312521356869/d246164d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-356869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer